

Recommendations for VoY CCG from York and Scarborough Medicines Commissioning Committee January 2016

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Tapentadol MR tablets (Palexia®)	Moderate to severe acute pain in adults	Approved		As detailed in treatment pathway	Amber – specialist initiation	
Biosimilar glargine - Abasaglar	Treatment of diabetes mellitus	Approved – for new patients only. To be prescribed by brand.	For use in new patients only	As per NICE guidance	Amber – specialist initiation	Likely to be 15% cheaper than Lantus. Switching not currently recommended.
VSL#3 Probiotic Food Supplement	An adjunct in the management of risk associated with c.difficile infection	No longer approved for use.	Due to apparent lack of effectiveness.	Not approved.	Black	Nil
Vortioxetine	Treatment of major depressive episodes in adults	Approved	Approved for use by NICE, in line with their recommendations	For depression that has not responded to two other antidepressants as per NICE TA	Amber – consultant initiation	As per NICE TA
Ciclosporin 1mg/ml eye drops	Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.	Approved	As per NICE TA369	As per NICE TA369	Amber - consultant initiation, then for GP prescribing with 6 monthly review by specialist	As per NICE TA
Omalizumab	Chronic urticaria	Approved as per NICE TA339	As per NICE TA339	This drug was NHSE commissioned but NHSE recently announced that it is now CCG commissioned.	Red – hospital only	As per NICE TA